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Abstract
Breast cancer can occur in either gender; however, it is rare in men, accounting for <1% of diagnosed cases. In a pre-
vious transcriptomic screen of male breast cancer (MBC) and female breast cancer (FBC) occurrences, we observed
that Stanniocalcin 2 (STC2) was overexpressed in the former. The aim of this study was to conﬁrm the expression of
STC2 in MBC and to investigate whether this had an impact on patient prognosis. Following an earlier transcriptomic
screen, STC2 gene expression was conﬁrmed by RT-qPCR in matched MBC and FBC samples as well as in tumour-
associated ﬁbroblasts derived from each gender. Subsequently, STC2 protein expression was examined immunohisto-
chemically in tissue microarrays containing 477 MBC cases. Cumulative survival probabilities were calculated using
the Kaplan–Meier method and multivariate survival analysis was performed using the Cox hazard model. Gender-
speciﬁc STC2 gene expression showed a 5.6-fold upregulation of STC2 transcripts in MBC, also supported by data
deposited in Oncomine™. STC2 protein expression was a positive prognostic factor for disease-free survival (DFS;
Log-rank; total p = 0.035, HR = 0.49; tumour cells p = 0.017, HR = 0.44; stroma p = 0.030, HR = 0.48) but had no
signiﬁcant impact on overall survival (Log-rank; total p = 0.23, HR = 0.71; tumour cells p = 0.069, HR = 0.59;
stroma p = 0.650, HR = 0.87). Importantly, multivariate analysis adjusted for patient age at diagnosis, node staging,
tumour size, ER, and PR status revealed that total STC2 expression as well as expression in tumour cells was an inde-
pendent prognostic factor for DFS (Cox regression; p = 0.018, HR = 0.983; p = 0.015, HR = 0.984, respectively). In
conclusion, STC2 expression is abundant in MBC where it is an independent prognostic factor for DFS.
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Introduction
Breast cancer (BC) is rare in men, accounting for <1%
of diagnosed cases. Treatment is informed by clinical
trials conducted in women, however, recent literature
suggests that, while similar histologically, there are
differences in genomic proﬁles between genders,
which may be exploited therapeutically [1–3].
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In our efforts to deﬁne biological differences in
male breast cancer (MBC) and female breast cancer
(FBC), we have previously conducted gene expression
analysis in matched MBC and FBC [3]. We observed
that Stanniocalcin 2 (STC2) was frequently overex-
pressed in MBC with indications that this gene
showed the greatest fold change between genders.
STC2 was identiﬁed in 1998, cloned from a human
osteosarcoma cDNA library and is related to a secreted
glycoprotein found in bony ﬁsh, where it plays a role
in calcium and phosphate homeostasis [4]. The STC2
gene encodes a 302 amino acid protein, which shares
30–39% homology with its sister molecule STC1
[4–6]. This 56 kDa secreted glycoprotein forms homo-
dimers, and has putative roles in cell survival, dor-
mancy, and metastasis. It has been suggested to
function in an autocrine/paracrine manner [5–10].
STC2 is expressed in many mammalian tissues,
including kidney, pancreas, intestine, and liver [8,11].
In FBC, STC2 is overexpressed compared to normal
human breast tissue [12]. STC2 is oestrogen respon-
sive, is frequently co-expressed with ER [13,14] and is
preferentially expressed in breast tumours of luminal
phenotype [15]. It is overexpressed in other cancers,
including lung [16], ovarian [17] as well as in colorec-
tal and gastric cancer in which it is thought to play a
role in cancer metastasis and progression [9,10]. How-
ever, in FBC, STC2 expression appears to be a favour-
able prognostic factor, associated with extended
disease-free and overall survival [15,18,19].
As STC2 has not been examined in the context of
MBC, the aim of this study was to validate our initial
microarray ﬁndings, then investigate the expression of
STC2 on clinical outcome in a large cohort of MBCs
by immunohistochemistry (IHC).
Materials and methods
Ethical approval and patient material
Leeds (East) Research Ethics Committee (06/Q1205
/156; 15/YH/0025) granted ethical approval. Initial
transcriptomics comparing genders used cases matched
for age, size, nodal, and survival status, as described
previously [3]. An additional three male and three
female age-matched ER+, PR+, HER− ductal carcino-
mas (fresh-frozen) were used to conﬁrm STC2 gene
expression. This was also performed on cultured ﬁbro-
blasts derived from a further four male and three
female samples of the same phenotype, prepared as
previously described [20].
Gender comparison of STC2 gene expression
Gene expression data for male and female BCs was
obtained using the Almac Breast Cancer DSA™ plat-
form as described previously [3]. Microarray data
are available on ArrayExpress (www.ebi.ac.uk/
arrayexpress) with accession number E-MTAB-4040.
The Oncomine™ platform was used for further data
mining. Transcriptomics data were conﬁrmed using
qRT-PCR, with reagents from Invitrogen unless other-
wise stated. RNA was extracted from fresh-frozen breast
tumours and cultured ﬁbroblasts (RNeasy kit, Qiagen
Cat #74106, Manchester, UK) according to manufac-
turer’s instructions. Prior to cDNA synthesis, genomic
DNA was removed using the TURBO DNA-free™ kit
(#AM1907). Following 90 s centrifugation at 8000 × g,
the supernatant was transferred to a fresh Eppendorf.
Levels and quality of RNA were assessed using Nano-
drop. RNA was then reverse transcribed: 1 μl Random
hexamers (50 μM, Invitrogen #N8080127, Paisley, UK),
1 μl of 10 mM dNTP stock (#D7295, Sigma-Aldrich,
Poole, UK) were added and incubated for 5 min at
65 C, then placed on ice for 2 min. Remaining reagents
were from SuperScript Reverse Transcriptase kit
(Invitrogen #18064014) unless otherwise speciﬁed. Per
sample, 4 μl 5× ﬁrst strand buffer, 2 μl 0.1 M dithiothrei-
tol and 1 μl RNase out (Invitrogen #10777019) were
added and samples incubated for 5 min at room tempera-
ture, then for 2 min at 42 C. Superscript II enzyme
(1 μl) was added to each sample, then samples were
heated at 42 C for 50 min, followed by a 15 min incu-
bation at 70 C. Samples were placed on ice for 2 min,
and cDNA concentration measured using Nanodrop.
For RT-qPCR, each well contained 90 ng cDNA,
10 μl TaqMan (Universal PCR) MasterMix (II), 1 μl
primer (TaqMan, ×20 Thermo Fisher Scientiﬁc, Lough-
borough, UK #4331182; STC1 (Hs00174970_m1),
STC2 (Hs01063215_m1), RPLP0 (Hs99999902_m1))
in a 20 μl reaction volume. cDNA was replaced with
dH2O in negative controls.
Reactions were heated to 50 C for 2 min then 90
C for 10 min followed by 40 cycles of 95 C for
15 s, 60 C for 1 min using a QS5 PCR machine. All
reactions were performed in triplicate. The mean
values for the replicates for each sample were calcu-
lated and expressed as cycle threshold. Gene expres-
sion levels of STC2 were expressed as 2−ΔΔCt, in
which ΔΔCt was normalised to the Ct value of RPLP0
(loading control) and to a calibrator sample when the
assay ran across more than one plate.
Immunohistochemistry
Levels of STC2 were examined by IHC in 477 MBCs
represented on tissue microarrays as described
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previously [3]. REMARK criteria were employed [21]
and patient characteristics are shown in Table 1. As
the cases covered several tissue microarrays (TMAs),
slides were batch stained for consistency. Slides were
placed on a heat block for 20 min and then placed into
1× access revelation solution (Menarini, High
Wycombe, UK), which was then heated to 125 C for
2 min in a pressure cooker. Slides were transferred for
1 min to 90 C automation wash buffer before being
placed under running water for 1 min. Slides were
transferred to TBS-T, then endogenous peroxidase
activity was quenched by adding 2 drops of peroxidase
block (Novocastra, Newcastle, UK, RE7101-CE) for
20 min. Slides were placed into TBS-Tween (0.1%)
for 5 min. Sections were blocked with 1:10 Casein
solution (Vector Laboratories® #SP-5020, Peterborough,
UK) in antibody diluent (Thermo Fisher Scientiﬁc
#003218) to block non-speciﬁc staining, then incubated
overnight at 4 C with STC2 antibody (manufacturer:
Atlas antibodies, supplier: Cambridge Bioscience,
Cambridge, UK, HPA045372) solution 1:400 in anti-
body diluent (isotype controls were diluted to the same
ﬁnal concentration). Antibody speciﬁcity was conﬁrmed
by the manufacturer by Western blot, IHC, and immuno-
ﬂuorescence, validated by the Human Protein Atlas
(http://www.proteinatlas.org) and has been used success-
fully in other published works [22]. We extended this by
optimising the concentration using a multi-tissue block
containing positive control tissue (human intestine and
liver), and a matched isotype control was used to deter-
mine antibody speciﬁcity. TMAs were batch stained
alongside the multi-tissue block as well as each TMA
including its own positive control tissue (human intestine
and liver). Slides were then washed three times in TBS-
T (5 min each). Novocastra kit (Leica Biosystems,
#RE7230-CE) was used for secondary staining according
to manufacturer guidelines. Following incubation with
DAB chromogen, slides were rinsed in 1× PBS (5 min)
followed by running tap water (1 min). Slides were then
counterstained with Mayer’s haematoxylin, blued with
Scotts tap water, then dehydrated and mounted with per-
manent aqueous medium DPX (Sigma-Aldrich). TMAs
were digitised (×10 magniﬁcation, Leica-Aperio AT2
ScanScope scanner; Leica Biosystems, Newcastle, UK).
Each TMA core was viewed and scored using
QuPath software [23]. In brief, TMAs were identiﬁed
using the TMA dearrayer tool, and the TMA map
imported. Tissue was detected using the ‘simple tissue
detection’ tool, so that any whitespace was excluded
from the analysis. Any confounding objects such as
tissue folds were removed manually at this stage. Cells
were detected using the ‘cell detection’ tool. Polygons
were drawn around a total of 7500 cells across 6 sepa-
rate TMAs, setting cell class as tumour or stroma.
These ‘training objects’ were then used to create a
detection classiﬁer, which recognises a variety of cel-
lular features to designate regions as tumour or stroma.
The cells were then classiﬁed as + [>0.1], ++ [>0.25],
+++ [>0.5], or negative [<0.1] (intensity cut-off points
shown in square brackets). The detection classiﬁer was
run on all TMAs. STC2 expression was assessed quan-
titatively using the H-score [13,22]. The H-score takes
into account both staining intensity and percentage of
cells stained, giving a range of 0–300 using the fol-
lowing formula: 1 × (% cells +) + 2 × (% cells +
+) + 3 × (% cells +++). Overall scores were averaged
from duplicate or triplicate cores, which represented a
case and a minimum of 200 tumour cells were
evaluated.
Statistical analysis
Unpaired two tailed t-tests were used for STC2 expres-
sion analysis. Receiver operating characteristic (ROC)
curves [24] were generated for tumour and stroma
Table 1. Clinicopathological characteristics for the IHC cohort
Characteristics
Mean age (range) 66 (30–97)
Mean follow-up, years (range) 3.9 (0.08–24.5)
Mean tumour size mm (range) 21.2 (1–86)
Number (%)
Histology
Invasive 419 (88)
DCIS 7 (1)
Mixed 15 (3)
Unknown 36 (8)
Grade
1 50 (10)
2 193 (41)
3 147 (31)
Unknown 87 (18)
Lymph node status
Positive 134 (28)
Negative 147 (31)
Unknown 196 (41)
ERα
Positive 404 (85)
Negative 30 (6)
Unknown 43 (9)
PR
Positive 352 (74)
Negative 74 (15)
Unknown 51 (11)
HER2
Positive 6* (1)
Negative 291 (61)
Unknown 180 (38)
DCIS, ductal carcinoma in situ.
*Conﬁrmed by FISH/CISH.
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cells using disease-free survival (DFS; from initial
diagnosis to the diagnosis of local or distant recur-
rence), and used to determine clinically relevant cut-
off points for STC2 H-scores. Univariate analysis was
then performed: the STC2 H-score data were dichoto-
mised using the identiﬁed STC2 cut-off points and
associations with both DFS and overall survival (OS;
from initial diagnosis to death) were analysed by Log-
rank test. Multivariate analysis was also performed
using the Cox proportional hazards regression model.
Clinicopathological variables included in multivariate
analysis were age at diagnosis, node staging, tumour
size, ER, and PR status. Patients were censored at the
last date they were known to be alive.
Results
Gene expression analysis
Comparing genders, we observed signiﬁcant upregula-
tion of STC2 in MBC compared to FBC, with a mean
fold-change of 5.61 (Figure 1A; p = 0.007), with RT-
qPCR of independent samples (3× male; 3× female)
suggesting a similar trend (Figure 1B). While this did
not reach statistical signiﬁcance, higher expression
was also seen using RT-qPCR of breast ﬁbroblasts
derived from a further four male and three female,
age-matched ER+, PR+, HER− ductal carcinomas
(Figure 1C) and conﬁrmed by interrogating
Oncomine™ (Figure 1D).
STC2 IHC
STC2 staining was predominantly cytoplasmic with
occasional foci of plasma membrane immunoreactiv-
ity. Representative images are shown in Figure 2A.
All samples showed some tumour cell STC2 positiv-
ity, and similarly in the stroma weak staining was
observed in the majority of cases. The breakdown of
staining intensities in tumour and stroma is shown in
Figure 2B. In addition, there was a signiﬁcant positive
correlation between STC2 H-scores in the tumour and
stroma, (Spearman rank ρ = 0.929, p < 0.001; Pearson
correlation R = 0.893, p < 0.001).
Impact of STC2 expression on survival
Cut-offs for high total, tumour, and stroma STC2
immunoreactivity, deﬁned by ROC curve analysis
were >90.5, >108.5, and >28.4, respectively (data not
shown). By univariate analysis, high-total STC2 as
well as in both tumour and stroma individually
impacted on DFS but not OS (Figure 3). Cases with
high levels of overall STC2, in tumour cells or stroma,
had signiﬁcantly longer DFS (Log-rank; p = 0.035,
p = 0.017, p = 0.03, respectively). For cases where
tumour cells had high levels of STC2, OS tended to be
longer although this was not signiﬁcant (Log-rank;
p = 0.069). There was no signiﬁcant difference in OS
for cases with high compared to low levels of STC2
total or in stroma (Log-rank; p = 0.23, p = 0.65,
respectively).
Multivariate analysis (with covariates patient age at
diagnosis, node staging, tumour size, ER, and PR sta-
tus) showed that total STC2 expression was an inde-
pendent prognostic factor for DFS but not OS (Cox
regression analysis; respectively p = 0.018, p = 0.911).
Similarly, high STC2 in tumour cells was an indepen-
dent prognostic factor for DFS, but not OS (Cox
Figure 1. STC2 overexpression in MBC. Signiﬁcantly higher
expression of STC2 was seen in MBC (n = 12) compared to FBC
(n = 10) (A), also implied by RT-qPCR analysis of three male and
three female cases (B) and in cultured primary ﬁbroblasts derived
from male (n = 4) and female (n = 3) BC (C). While the number
of MBC cases in the Oncomine™ analysis is low (n = 4, com-
pared with 322 females), data mining showed higher expression
of STC2 in MBC versus FBC (D). Data on graphs are displayed as
mean  SD, except (D) where data are displayed as median, 90th
percentile and 10th percentile (minimum and maximum values
also shown). M, male; F, female.
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regression analysis; respectively, p = 0.015,
p = 0.822). Patients with tumours containing stroma
with high STC2 tended to have longer DFS, however,
this was not signiﬁcant (Cox regression analysis;
p = 0.218). Nor was there any relationship between
stroma STC2 levels and OS (Cox regression analysis;
p = 0.65). Data are summarised in Table 2, with sig-
niﬁcant values in bold underline.
Discussion
A number of studies are beginning to show that STC2
expression is a favourable prognostic factor in BC;
however, it has not been studied previously in the con-
text of MBC. With growing recognition that male and
female BC may not be identical, there is increasing
interest in elucidating the biology of MBC, to assist in
deﬁning indicators of survival. The key ﬁndings in this
study were elevated expression of STC2 RNA in male
versus female BC and that both total STC2 protein
and its expression in tumour cells was an independent
predictor of patient survival in MBC.
Using cell line models, it has been suggested that the
association between STC2 expression and favourable
outcome may be a result of its ability to repress inva-
sive behaviour [25]. Hou et al [25] found enhanced
migration, motility, and expression of the transcription
factors Slug and Twist in BC cell lines where STC2
was silenced, which following radiation were also more
anti-apoptotic compared to non-silenced control cells.
Similarly, Raulic et al [5] noted a reduction in cell
motility when BC cell lines were stably transfected
with STC2, as well as decreased cell viability after
serum withdrawal and reduced proliferation. This ﬁnd-
ing may be unique to BC as, in other cancers, including
neuroblastoma [26], lung [16], ovarian [17], and gastric
cancer [9], STC2 expression has been reported to pro-
mote metastasis and is thought to be a poor prognostic
factor. These seemingly opposing roles of STC2 again
indicate its ability to mediate its effects through differ-
ent signaling pathways dependent on the cellular con-
text, possibly through dysregulation of calcium and
phosphate dependent signaling [25].
In a study of 72 paired primary and metastatic BCs
[7], STC2 expression was signiﬁcantly higher in pri-
mary tumours that showed late relapse, leading the
authors to suggest that STC2 may be involved in
tumour dormancy. This is of particular interest in BC,
a disease known for its tendency to recur many years
after a patient has been in remission. Formation of dis-
tant metastases is believed to be an early event in BC
Figure 2. Representative images of STC2 staining in MBC TMAs.
The top panel shows examples of the various staining intensities
in individual TMA cores, with higher magniﬁcation areas shown
in the yellow outlined inserts. Black outlined inserts indicate foci
of plasma membrane staining. The graph below shows the % of
TMA samples which were categorised into each ‘intensity’ group
(where the majority of tumour cells had at least the given inten-
sity). +, weak, ++, medium staining, +++, strong staining. Images
scanned at x20 objective magniﬁcation.
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Figure 3. Kaplan–Meier survival curves showing impact of STC2 staining H-score in tumour and stroma on patient prognosis. High STC2
H-scores in tumour cells (A), stroma (C) and total (E) were associated with longer DFS (p = 0.017, p = 0.03, p = 0.035, respectively), but
had no signiﬁcant impact on OS for tumour (B), stroma (D) or total (F) (p = 0.069, p = 0.65, p = 0.23). Grey line, high STC2 H-score;
black line, low STC2 H-score, Log-rank test. Cases were dichotomised by STC2 H-score: H-score cut-off point was 108.5 for tumour cells
(DFS n = 28 low, n = 23 high; OS n = 76 low, n = 73 high); 28.4 for stroma (DFS n = 16 low, n = 35 high; OS n = 49 low, n = 100 high)
and 90.5 for total staining (DFS n = 28 low, n = 23 high; OS n = 77 low, n = 72 high). HR, hazard ratio, followed by conﬁdence intervals
shown in brackets.
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[27], but it is not fully understood why secondary can-
cer arises in only a subgroup of patients. Both this
study and our data suggest that low-tumour levels of
STC2 may have potential as a biomarker to identify a
subgroup of patients at risk of early relapse in BC.
Previously, STC2 has only been evaluated in the
context of its expression in tumour cells. Here, we
noted that STC2 was found not only in the tumour
cells but also in stroma. Univariate analysis showed
that patients with tumours with STC2 in both tumour
and stroma had signiﬁcantly longer DFS. As STC2 is
a secreted glycoprotein [5], with the secreted form of
STC2 reported to be the most abundant in some
tissues [28], it is difﬁcult to conﬁrm whether it is
produced mainly in the tumour cells or in stroma. Our
RT-qPCR data support the hypothesis that it is predom-
inantly produced by the tumour cells, showing approxi-
mately four-fold higher expression in frozen tissue
containing both tumour and stroma cells, compared to
expression in cultured tumour-associated ﬁbroblasts.
However, these data were not directly comparable; the
ﬁbroblasts used in this study were not derived from the
tumours used for our original transcriptomic screen or
the RT-qPCR validation used here, and it was not pos-
sible to test STC2 expression in tumour cells isolated
from BC. While efforts to establish tumour epithelial
cell cultures from male BC have been fruitless thus far,
we were able to successfully generate tumour-
associated ﬁbroblasts. To our knowledge this is the ﬁrst
time this approach has been used experimentally and
offers a new angle to study male BC.
STC2 expression appeared higher in MBC than in
FBC and this was corroborated through interrogation
of Oncomine™. For the transcriptomic part of our
study, we acknowledge the number of cases of male
BC available was low. However, this is not unusual
when studying a rarer cancer type. This is also true of
publically accessible data mining platforms such as
Oncomine™, which also have very small numbers of
male BC, with the largest comparative dataset we
could analyse from this having only four male cases.
Nevertheless, in other cancers (lung, renal, leukaemia,
and colorectal), no gender-speciﬁc differences were
identiﬁed in STC2 expression (data not shown).
It has been proposed that high expression of Stan-
niocalcins in primary BC may predict late BC recur-
rence, with both STC1 and STC2 implicated [7].
While this work was under review, expression of
STC1 but not STC2 in the primary tumour was predic-
tive of late recurrence in a large cohort of Danish BCs
[29]. Taken together, at least in BC, this adds weight
to the notion that STC2 appears to be a good prognos-
tic factor for both genders, following observations inTa
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FBC, where elevated STC2 expression was associated
with longer OS and DFS [15,18,19,30]. However, in
our study, there was a reduction in its signiﬁcance on
multivariate compared to univariate analysis. This
might be explained by the fact that we were unable to
obtain complete clinicopathological data from some
centers that contributed cases for our TMAs; as some
of this was necessary for multivariate analysis, a note
of caution is warranted.
It has been additionally reported that STC2 is asso-
ciated with ER+ FBC [13], supported by our ﬁndings
that ﬁbroblasts from ER+ MBC, or FBC expressed
higher levels of STC2 compared to those from ER−
breast tumours. As exempliﬁed in the two largest
reported studies on MBC, which examined thousands
of patients, ER expression is very common in MBC
[3,31], hence it is not surprising to see the same
association.
In summary, while overexpressed in male compared
to female BC, STC2 appears to be a good prognostic
factor, irrespective of gender.
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